Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid LeukemiaAlexandre Iat, Sylvain Garciaz, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 2
The Prognostic and Predictive Value of <i>RUNX1</i> Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort StudyRebecca P. Bystrom, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 0
POSTER: MDS-730 Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naïve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alfa (EA) in the COMMANDS TrialGuillermo Garcia‐Manero, Valeria Santini, Sameer Kalsekar et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
AML-508: Phase 1 Study of Mitotic Checkpoint Inhibitor BAL0891 as Monotherapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaEric J. Feldman, Courtney D. DiNardo, Byung Sik Cho et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0